NDA 20-862

Bone Care International
Attention: Ms. Darlene Kyllo, RAC
Director, Compliance, Quality & Regulatory Affairs
One Science Court
Madison, WI 53711

Dear Ms. Kyllo:

Please refer to your new drug application (NDA) dated March 7, 1998, received March 9, 1998, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Hectorol (doxercalciferol) Capsules, 2.5 mcg.

We acknowledge receipt of your submissions dated March 16 and 25, April 8 and 27, May 22, June 10, July 16, October 8, November 4, 5, 16, and 24, and December 3, 7, 14, 17, 22, 25, and 30, 1998, and January 12, 14(2), and 28, February 1 and 12, April 2, 16, and 22, May 5, 21, and 27, and June 1, 3, 8, and 9 (3), 1999. Your December 17, 1998, submission was a major amendment.

This new drug application provides for the use of Hectorol (doxercalciferol) Capsules to reduce elevated iPTH levels in the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.

We have completed the review of this application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the agreed upon labeling text. Accordingly, the application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert, immediate container, and carton labels, submitted June 9, 1999). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 20-862." Approval of this submission by FDA is not required before the labeling is used.

We remind you of your Phase 4 commitments specified in your submission dated May 27, 1999. These commitments, which you agreed to complete and submit the revised regulatory tests and testing results by July 1, 2000, are listed below.

The Phase 4 Commitments are Chemistry /Manufacturing related.

Protocols, data, and final reports should be submitted to this NDA as correspondence. In addition, under 21 CFR 314.82(b)(2)(vii), we request that you include a status summary of each commitment in your annual report to this NDA. The status summary should include expected completion and submission dates and any changes in plans since the last annual report. For administrative purposes, all submissions, including supplements, relating to these Phase 4 commitments should be clearly designated "Phase 4 Commitments."

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We are waiving the pediatric study requirement for this application at this time.

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please send one copy to the Division of Metabolic and Endocrine Drug Products and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Randy Hedin, R.Ph., Senior Regulatory Management Officer, at (301) 827-6392.

Sincerely,

John K. Jenkins, M.D., F.C.C.P.
Director
Office of Drug Evaluation II
Center for Drug Evaluation and Research